💊 Piramal Pharma Q2 FY2025-26 Results: Revenue Falls 9%, Company Reports ₹99 Crore Loss — Detailed Analysis and Management Guidance

Piramal Pharma Limited (PPL), one of India’s leading integrated pharmaceutical companies, announced its Q2 FY2025-26 financial results, revealing a decline in revenue and a net loss for the quarter.
Despite short-term headwinds, management remains confident about the company’s long-term transformation through focused investments in CDMO, consumer healthcare, and complex generics.

Let’s take a detailed look at the financial performance, business analysis, and management commentary for Piramal Pharma’s Q2 FY2025-26 results.

📊 Piramal Pharma Q2 FY2025-26 Financial Highlights

(Sources: Company filings, NSE reports, EquityBulls, Livemint)

💡 Overview: What the Numbers Tell Us

Piramal Pharma reported consolidated revenue of ₹2,044 crore for Q2 FY26, down 9% year-on-year due to weak performance in its Contract Development and Manufacturing Organization (CDMO) business.

The company also reported a net loss of ₹99 crore, compared to a profit of ₹23 crore in the same quarter last year.
EBITDA came in at ₹224 crore, representing a sharp 44% drop year-on-year, as margins were squeezed by cost pressures and lower capacity utilization in CDMO operations.

However, the Consumer Healthcare (CHG) and In-Hospital Generics (ICH) segments performed relatively well, providing some cushion against the downturn.

🧾 Segment-Wise Performance Analysis

⚗️ 1. CDMO (Contract Development & Manufacturing Organization)

This is Piramal Pharma’s largest and most global-facing segment, contributing nearly half of total revenues.
In Q2 FY26, the CDMO business reported revenue of ₹1,044 crore, a sharp 21% YoY decline.

Key reasons for the decline:

• Inventory destocking by major biopharma customers.

• Delays in order flow from global partners due to funding constraints.

• Lower demand for COVID-related projects compared to the previous year.

EBITDA margins for this segment fell significantly due to lower plant utilization and a weak product mix.

Management Insight:

“The CDMO business faced short-term headwinds due to destocking and project delays. However, we are confident about a recovery in H2 FY26 as RFP activity has started picking up,”
said Nandini Piramal, Chairperson, Piramal Pharma Ltd.

🛍️ 2. Consumer Healthcare (CHG)

The Consumer Healthcare business — which includes brands such as Lacto Calamine, Little’s, Tetmosol, and Polycrol — remained relatively stable, with revenues of around ₹644 crore.

Highlights:

• Power brands witnessed mid-teen growth, driven by innovation and e-commerce sales.

• Focus on digital-first marketing and direct-to-consumer platforms improved brand visibility.

• Despite a sluggish overall market, CHG helped provide stability to the company’s topline.

This segment continues to be a bright spot and a steady revenue contributor amid volatility in the global CDMO market.

💉 3. In-Hospital / Critical Care Generics (ICH)

The In-Hospital Generics segment posted a strong 15% YoY growth, with revenue of ₹319 crore in Q2 FY26.

Key drivers:

• Strong demand in India and emerging markets.

• New product launches and better penetration in hospitals.

• Gradual recovery in export markets post-regulatory normalization.

This segment is gradually becoming a consistent profit driver for Piramal Pharma, balancing the volatility seen in the CDMO business.

💰 Profitability and Margins

The decline in profitability was primarily due to lower CDMO volumes and fixed cost absorption challenges.
In contrast, the consumer and hospital generics segments helped prevent a deeper fall in overall performance.

📈 Balance Sheet and Debt Position

• Net Debt: ₹3,971 crore (reduced from ₹4,199 crore as of March 2025).

• Debt-to-EBITDA Ratio: Below 3x, indicating controlled leverage.

• Capex: The company continues to invest selectively in new high-value CDMO capacities such as sterile fill-finish, Antibody-Drug Conjugates (ADCs), and complex generics.

Management Focus:

“We remain disciplined on capital allocation and continue to deleverage our balance sheet while investing in long-term growth drivers,”
— Nandini Piramal, Chairperson.

🧭 Management Outlook and Guidance for FY2025-26

Despite the weak quarter, management reiterated its confidence in a stronger H2 FY26 and beyond, driven by recovery in global demand and new business wins.

🔹 Key Management Guidance:

• CDMO Recovery: RFPs (Request for Proposals) and client inquiries are picking up; order flow expected to improve in Q3–Q4.

• Consumer Healthcare Growth: Continued focus on innovation, digital marketing, and e-commerce-led growth.

• ICH Expansion: Plans to expand product portfolio across India, LATAM, and MENA regions.

• Operational Efficiency: Cost optimization initiatives underway to improve margins in H2.

• Capital Discipline: Focus on debt reduction and better working capital efficiency.

“The second half of FY26 typically contributes a larger share of revenue and profit for Piramal Pharma. With early signs of recovery in CDMO and stable domestic business, we expect improved performance ahead,”
— Management Statement, November 2025.

🧠 Analyst and Market Reactions

Analysts viewed Piramal Pharma’s Q2 results as disappointing yet understandable, given global headwinds in the CDMO space.

• ICICI Securities: “CDMO slowdown is cyclical; we expect a gradual recovery from Q4 FY26.”

• Motilal Oswal: “CHG and ICH segments are performing well and provide stability amid volatility.”

• HDFC Securities: “Debt reduction is positive, but margin expansion will be key for rerating.”

🧩 Key Factors to Watch Going Forward

1. CDMO order recovery in H2 FY26 and FY27.

2. Consumer Healthcare growth trajectory and margin improvement.

3. ICH expansion across domestic and export markets.

4. R&D investments in high-value products like ADCs.

5. Debt management and cash flow discipline.

6. Global biopharma funding trends impacting contract manufacturing.

🔍 Detailed Comparison: Q2 FY25-26 vs Q1 FY25-26 vs Q2 FY24-25

📊 Investor Takeaway

✅ Positives:

• Diversified portfolio (CDMO + CHG + ICH) limits downside risk.

• Debt reduction continues.

• Consumer healthcare remains steady.

• Strong base for recovery in H2 FY26.

⚠️ Challenges:

• CDMO demand slowdown affecting revenue and margins.

• Weak profitability due to under-utilized facilities.

• Global uncertainty delaying new orders.

Investor Sentiment:
Short-term cautious; long-term constructive — once CDMO rebounds, PPL can regain strong growth momentum.

🏁 Conclusion: Piramal Pharma’s Transition Phase

Q2 FY2025-26 was a challenging quarter for Piramal Pharma.
Revenue dropped 9% YoY to ₹2,044 crore, and the company reported a loss of ₹99 crore due to continued weakness in the CDMO segment.

However, the Consumer Healthcare and In-Hospital Generics businesses showed resilience, supporting the company through the turbulence. With a leaner balance sheet, renewed focus on high-value manufacturing, and improving global order trends, Piramal Pharma appears positioned for a recovery in the second half of FY26.